BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

21 related articles for article (PubMed ID: 32436187)

  • 1. Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group.
    Merath K; Bagante F; Beal EW; Lopez-Aguiar AG; Poultsides G; Makris E; Rocha F; Kanji Z; Weber S; Fisher A; Fields R; Krasnick BA; Idrees K; Smith PM; Cho C; Beems M; Schmidt CR; Dillhoff M; Maithel SK; Pawlik TM
    J Surg Oncol; 2018 Apr; 117(5):868-878. PubMed ID: 29448303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a novel nomogram for pretreatment prediction of liver metastasis in pancreatic cancer.
    Chen S; Chen S; Lian G; Li Y; Ye X; Zou J; Li R; Tan Y; Li X; Zhang M; Huang C; Huang C; Zhang Q; Huang K; Chen Y
    Cancer Med; 2020 May; 9(9):2971-2980. PubMed ID: 32108437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrence of Non-functional Pancreatic Neuroendocrine Tumors After Curative Resection: A Tumor Burden-Based Prediction Model.
    Dong DH; Zhang XF; Lopez-Aguiar AG; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Pawlik TM
    World J Surg; 2021 Jul; 45(7):2134-2141. PubMed ID: 33768309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updated Principles of Surgical Management of Pancreatic Neuroendocrine Tumours (pNETs): What Every Surgeon Needs to Know.
    de Ponthaud C; Menegaux F; Gaujoux S
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Recurrence of Neuroendocrine Liver Metastasis After Curative Hepatectomy: Risk Factors, Prognosis, and Treatment.
    Zhang XF; Beal EW; Chakedis J; Lv Y; Bagante F; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Weiss M; Pawlik TM
    J Gastrointest Surg; 2017 Nov; 21(11):1821-1830. PubMed ID: 28730354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors.
    Pulvirenti A; Javed AA; Landoni L; Jamieson NB; Chou JF; Miotto M; He J; Gonen M; Pea A; Tang LH; Nessi C; Cingarlini S; D'Angelica MI; Gill AJ; Kingham TP; Scarpa A; Weiss MJ; Balachandran VP; Samra JS; Cameron JL; Jarnagin WR; Salvia R; Wolfgang CL; Allen PJ; Bassiy C
    Ann Surg; 2021 Dec; 274(6):1051-1057. PubMed ID: 31567347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-Institutional Development and External Validation of a Nomogram for Prediction of Extrahepatic Recurrence After Curative-Intent Resection for Hepatocellular Carcinoma.
    Wei T; Zhang XF; Xue F; Bagante F; Ratti F; Marques HP; Silva S; Soubrane O; Lam V; Poultsides GA; Popescu I; Grigorie R; Alexandrescu S; Martel G; Workneh A; Guglielmi A; Hugh T; Aldrighetti L; Endo I; Pawlik TM
    Ann Surg Oncol; 2021 Nov; 28(12):7624-7633. PubMed ID: 34019181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Extent of Liver Resection Among Patients with Neuroendocrine Liver Metastasis: an International Multi-institutional Study.
    Sham JG; Ejaz A; Gage MM; Bagante F; Reames BN; Maithel S; Poultsides GA; Bauer TW; Fields RC; Weiss MJ; Marques HP; Aldrighetti L; Pawlik TM; He J
    J Gastrointest Surg; 2019 Mar; 23(3):484-491. PubMed ID: 29980977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome.
    Xiang JX; Zhang XF; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
    J Surg Oncol; 2018 Dec; 118(7):1096-1104. PubMed ID: 30261105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
    Leng X; He W; Yang H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Liu H; Yang H; Li T; Zhang X; Li Q; Wang G; Mao T; Guo X; Lin T; Liu M; Fu J; Han Y
    Ann Surg; 2021 Dec; 274(6):e1022-e1029. PubMed ID: 31855875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-institutional Development and External Validation of a Nomogram Predicting Recurrence After Curative Liver Resection for Neuroendocrine Liver Metastasis.
    Xiang JX; Zhang XF; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
    Ann Surg Oncol; 2020 Oct; 27(10):3717-3726. PubMed ID: 32436187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current status of surgical treatment for neuroendocrine liver metastases].
    Zhao H
    Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(14):992-995. PubMed ID: 35399017
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.